AstraZeneca announces sale of its AMAZE disease management platform to Huma

The two companies will continue to collaborate on digital healthcare solutions

AstraZeneca has sold its AMAZETM disease management platform and entered in to a collaboration agreement with Huma focused on scaling digital health innovation to help improve patient outcomes. The companies’ shared ambition is to improve clinical outcomes by deploying digital health solutions that bridge the gap between patients and clinicians, which only widened due to the COVID-19 pandemic.

AstraZeneca has invested in the development and clinical validation of the patient-centered AMAZETM disease management platform since 2020 to improve the care of patients with chronic diseases. The company has conducted two clinical studies in heart failure and asthma at a leading US academic medical center and a community practice, with the goals of improving patient engagement, care-team communication, and clinical outcomes while reducing healthcare costs.

The AMAZETM platform shares critical data with clinicians on patient health progress and enables healthcare providers and patients to message each other through the app. Patients can also get alerts concerning their daily logs, and receive reminders, air quality notifications, disease education, medication details and more.

Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said, "We are very excited to be working more closely with Huma across our digital health initiatives. We believe digital can expand access to healthcare, advance clinical research, and identify existing gaps in care. Additionally, with this innovative partnership, we will bring a combination of technology along with expertise in research and drug development to global decentralized clinical trials advancing the science of "right patient, right therapy, right time."

Together, AstraZeneca and Huma are committed to leveraging their technology and expertise to broaden the AMAZETM footprint and launch companion applications, increase decentralized clinical trials, improve patient engagement, as well as clinical outcomes while reducing healthcare costs.

Dan Vahdat, CEO of Huma said, “Our track record of scaling innovation has set the stage for this important partnership with one of the world’s largest biopharmaceutical companies. I am excited to have AstraZeneca’s support to build upon our 10-year experience of delivering digital-first solutions across healthcare and clinical trials. The combination of pioneering leadership, global-reach, deep medical knowledge and digital innovation will enable our award-winning platform to help more people live longer, fuller lives."    

Digital technology, such as AMAZETM, can transform healthcare delivery. Its ability to quickly send key insights on patient health to clinicians, despite potential obstacles due to a pandemic, can help every patient live life without limits.

Karan Arora, Chief Commercial Digital Officer, AstraZeneca, said: " This collaboration marks an important moment as it is a first for AstraZeneca in the digital health space as well as in the industry for chronic diseases. With Huma, we are accelerating AstraZeneca’s ambition to achieve earlier diagnosis and treatment for patients with chronic diseases so they can lead better, more fulfilling lives."

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZenecaUS.

Media Inquiries

Brendan McEvoy


+1 302 885 2677



US Media Mailbox:           

# # #